RTTNews | Sep 23, 2021 07:54AM EDT

07:54 Thursday, September 23, 2021 (RTTNews.com) - TransCode Therapeutics Inc. (RNAZ) announced publication in Cancer Nanotechnology of preclinical data supporting therapeutic potential of TTX-MC138(MN-anti-miR10b) in metastatic breast cancer.

In Thursday pre-market trade, RNAZ was trading at $3.09 up $0.47 or 17.94%.

The study confirmed the biodistribution of TTX-MC138 in models of metastatic cancer, supporting TransCode's TTX platform for delivery of RNA targeted therapy to metastatic solid tumors.

The company looks forward to its Phase 0 study which has the potential to establish clinical proof-of-concept for this therapy.

TransCode expects to file an exploratory investigational new drug (eIND) application for TTX-MC138 in the first quarter of 2022 to support a Phase 0 study in patients with metastatic cancer.

Under an eIND, FDA approval may be obtained more quickly and at lower cost than with a traditional IND for therapeutic agents.

Read the original article on RTTNews ( https://www.rttnews.com/3227801/transcode-preclinical-data-supports-therapeutic-potential-of-ttx-mc138-in-metastatic-breast-cancer.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved